Royal Wolverhampton NHS Trust

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

Caristo Diagnostics Piloting New Cardiac Disease Diagnostic Technology in UK NHS Hospitals

Retrieved on: 
Wednesday, July 12, 2023

OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited, a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.

Key Points: 
  • OXFORD, England, July 12, 2023 /PRNewswire/ -- Caristo Diagnostics Limited , a global leader in cardiac and vascular disease diagnostics and risk prediction, announces today that it is deploying its latest CaRi-Heart® technology in National Health Service (NHS) hospitals as part of a new coronary artery disease (CAD) management pathway pilot.
  • The new pilot supported by NHS England will involve five NHS trusts, including University Hospitals of Leicester NHS Trust, Liverpool Heart and Chest Hospitals NHS Foundation Trust, Milton Keynes University Hospital NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust, and Royal Wolverhampton NHS Trust.
  • The latest CaRi-Heart platform was released recently for UK and EU markets and can detect both coronary inflammation and atherosclerosis (plaque), based on routine cardiac CT scans.
  • "Caristo and our clinical partners are excited about this ground-breaking clinical initiative supported by NHS England", said Frank Cheng, Caristo Diagnostics CEO, "We anticipate that this real-world implementation will pave the way for the CaRi-Heart technology to be broadly adopted both across the NHS and around the world".

MHRA Grants Marketing Authorisation for Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

Retrieved on: 
Wednesday, July 5, 2023

Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Key Points: 
  • Incyte Biosciences UK today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
  • Opzelura is the first and only approved treatment in the United Kingdom (UK) to offer eligible patients with non-segmental vitiligo support for repigmentation.
  • “Today’s MHRA approval is welcome news for dermatologists and people with vitiligo seeking treatment who until now have had limited options.
  • “We are delighted to announce the MHRA approval of Opzelura for people living with non-segmental vitiligo with facial involvement,” said Peter Williams, General Manager, Incyte United Kingdom and Ireland.

Intuitive becomes largest robotic-assisted surgery provider to be accredited by the Royal College of Surgeons of England

Retrieved on: 
Wednesday, October 19, 2022

SUNNYVALE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Today, Intuitive announced that it has become the largest provider of robotic-assisted surgical technology training to be accredited by the Royal College of Surgeons of England (RCS England).

Key Points: 
  • SUNNYVALE, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Today, Intuitive announced that it has become the largest provider of robotic-assisted surgical technology training to be accredited by the Royal College of Surgeons of England (RCS England).
  • Intuitive is the pioneer of robotic-assisted surgery and provides training on its robotic technology to surgeons and their teams on its da Vinci Surgical Systems.
  • The Royal College of Surgeons of England is a world leader of surgical education and provides quality assurance for any surgical training run in the UK and globally.
  • We are proud that the Royal College of Surgeons has recognized Intuitive for the quality of our robotic surgery technology training and education, which combines technology and skills training with peer-to-peer learning.

Babylon accelerates momentum, more than doubling its signed value-based care lives in the second half of this year so far

Retrieved on: 
Monday, October 18, 2021

Babylon will increase the number of Americans served through its value-based care program with the addition of 63k lives in Georgia and Mississippi, as at the contract date.

Key Points: 
  • Babylon will increase the number of Americans served through its value-based care program with the addition of 63k lives in Georgia and Mississippi, as at the contract date.
  • This will be further supplemented by 17k lives in California at the beginning of 2022.
  • Babylon is a world leading, digital-first, value-based care company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth.
  • Babylon is re-engineering healthcare, shifting the focus from sick care to preventative healthcare so that patients experience better health, and reduced costs.

Babylon accelerates momentum, more than doubling its signed value-based care lives in the second half of this year so far

Retrieved on: 
Monday, October 18, 2021

Babylon will increase the number of Americans served through its value-based care program with the addition of 63k lives in Georgia and Mississippi, as at the contract date.

Key Points: 
  • Babylon will increase the number of Americans served through its value-based care program with the addition of 63k lives in Georgia and Mississippi, as at the contract date.
  • This will be further supplemented by 17k lives in California at the beginning of 2022.
  • Babylon is a world leading, digital-first, value-based care company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth.
  • Babylon is re-engineering healthcare, shifting the focus from sick care to preventative healthcare so that patients experience better health, and reduced costs.

Totara supports 350,000 NHS staff through COVID-19 with Think Learning

Retrieved on: 
Wednesday, September 15, 2021

SAN FRANCISCO, Sep. 15, 2021 /PRNewswire-PRWeb/ -- Think Learning is the leading Totara Learn supplier to the UK healthcare sector with around 25% (350,000 employees) of NHS employees in England now accessing a Totara learning platform supported by Think Learning.

Key Points: 
  • SAN FRANCISCO, Sep. 15, 2021 /PRNewswire-PRWeb/ -- Think Learning is the leading Totara Learn supplier to the UK healthcare sector with around 25% (350,000 employees) of NHS employees in England now accessing a Totara learning platform supported by Think Learning.
  • The Totara platform has allowed the NHS to rapidly onboard thousands of volunteers and medical staff returning to work to deliver the vaccination program during 2021.
  • Maged Fahmy, Chief Commercial Officer at Totara, said: "We are extremely proud of the fact that so many NHS Trusts chose Totara as their learning platform of choice throughout the pandemic.
  • Think Learning is a fast-growing UK Totara Partner, providing platform and consultancy services in a range of sectors.

Royal Wolverhampton NHS Trust (RWT) and Babylon bring digital-first, value-based healthcare to over 55,000 people across Wolverhampton

Retrieved on: 
Monday, August 16, 2021

LONDON and WOLVERHAMPTON, United Kingdom, Aug. 16, 2021 /PRNewswire/ -- Royal Wolverhampton NHS Trust (RWT) and Babylon today announced they have extended their partnership to bring Babylon's value-based care service – Babylon 360 – to c.55,000 people across Wolverhampton. This collaboration builds on the existing partnership between  RWT and Babylon, with the aim of introducing an integrated and accessible digital-first healthcare experience for Wolverhampton residents.

Key Points: 
  • LONDON and WOLVERHAMPTON, United Kingdom, Aug. 16, 2021 /PRNewswire/ -- Royal Wolverhampton NHS Trust (RWT) andBabylon today announced they have extended their partnership to bring Babylon's value-based care service Babylon 360 to c.55,000 people across Wolverhampton.
  • This collaboration builds on the existing partnership between RWT and Babylon, with the aim of introducing an integrated and accessible digital-first healthcare experience for Wolverhampton residents.
  • RWT is a highly innovative, vertically-integrated organisation, with nine GP practices, three hospitals and over twenty community healthcare sites across Wolverhampton and Staffordshire.
  • Trust Chief ExecutiveProfessor David Loughton CBE, said: "The partnership with Babylon is an exciting one for us as a Trust.

Royal Wolverhampton NHS Trust (RWT) and Babylon bring digital-first, value-based healthcare to over 55,000 people across Wolverhampton

Retrieved on: 
Monday, August 16, 2021

LONDON, and WOLVERHAMPTON, United Kingdom, Aug. 16, 2021 /PRNewswire/ -- Royal Wolverhampton NHS Trust (RWT) and Babylon today announced they have extended their partnership to bring Babylon's value-based care service – Babylon 360 – to c.55,000 people across Wolverhampton. This collaboration builds on the existing partnership between  RWT and Babylon, with the aim of introducing an integrated and accessible digital-first healthcare experience for Wolverhampton residents.

Key Points: 
  • LONDON, and WOLVERHAMPTON, United Kingdom, Aug. 16, 2021 /PRNewswire/ -- Royal Wolverhampton NHS Trust (RWT) andBabylon today announced they have extended their partnership to bring Babylon's value-based care service Babylon 360 to c.55,000 people across Wolverhampton.
  • This collaboration builds on the existing partnership between RWT and Babylon, with the aim of introducing an integrated and accessible digital-first healthcare experience for Wolverhampton residents.
  • Trust Chief ExecutiveProfessor David Loughton CBE, said: "The partnership with Babylon is an exciting one for us as a Trust.
  • Babylon is reengineering healthcare, shifting the focus from sick care to preventative healthcare so that patients experience better health, and reduced costs.